Advances in Therapy Journal Citation Rate 2026
0741-238X
eISSN 1865-8652
Adis, Springer Healthcare
GB
Q1 Quartile Established Impact
About Advances in Therapy
Advances in Therapy (AT) is a peer-reviewed academic journal covering Asthma and respiratory diseases and Diabetes Management and Research, published by Adis, Springer Healthcare in GB, catalogued under ISSN 0741-238X (e-ISSN 1865-8652). As of 2026, it has a 2025 2-Year Citation Rate (OpenAlex) of 3.51 (Q1 quartile) — the average number of citations its recent articles received over a two-year window, computed from OpenAlex open citation data, not the Clarivate (JCR) Impact Factor. It operates a subscription model (APC ~$4390 USD).
Advances in Therapy Citation Rate 2026 — In Context
Advances in Therapy has a 2025 2-Year Citation Rate (OpenAlex) of 3.51, placing it in the Q1 quartile within the Asthma and respiratory diseases research area. This is the average number of citations the journal's recent articles received over a two-year window, computed from OpenAlex open citation data — not the Clarivate (JCR) Journal Impact Factor.
Advances in Therapy operates a subscription-based publishing model — readers access articles through institutional subscriptions or pay-per-view.
Researchers looking to publish in Advances in Therapy should review the journal's submission tips and verify the latest indexing status against Scopus, DOAJ, and Web of Science using our indexing tracker. To compare Advances in Therapy against similar journals in the field, use our journal comparison tool.
Submission Tips for Advances in Therapy
- Budget $4390 for the Article Processing Charge. Check if your institution or funder covers OA fees.
- This journal covers Asthma and respiratory diseases, Diabetes Management and Research, Diabetes Treatment and Management. Ensure your manuscript aligns with these scope areas to avoid desk rejection.
How Advances in Therapy Compares
Compared against 18 journals in the same research areas.
| ISSN (Print) | 0741-238X |
|---|---|
| ISSN (Online) | 1865-8652 |
| Publisher | Adis, Springer Healthcare |
| Country | United Kingdom |
| APC / Cost | $4390 USD |
In-depth profile & metrics
Advances in Therapy is published by Adis, Springer Healthcare and based in United Kingdom. It runs on a subscription or hybrid model with an article-processing charge of USD 4390.
In our subject taxonomy, Advances in Therapy is classified under Asthma and respiratory diseases, Diabetes Management and Research, Diabetes Treatment and Management and Glaucoma and retinal disorders.
Advances in Therapy is indexed in OpenAlex. OpenAlex tracking provides an open, citable record of its output even where commercial indexing is absent.
Its most recent citation rate stands at 3.508.
Research Areas
Links
Continue on JournalsHub
Put what you just read into practice with these free tools.
Frequently Asked Questions about Advances in Therapy
Live Indexing Status
Updated April 2026Track real-time indexing metrics to ensure this journal meets your academic requirements.
Citation Rate
Historical Trend
Initial data points onlyCitation Rate by Year
| Year | Value | Source |
|---|---|---|
| 2025 | 3.508 | 2-Year Mean Citedness (OpenAlex) |
Metrics are sourced from OpenAlex, DOAJ and Scopus and reflect the latest data we hold. The headline figure is a 2-year citation rate (OpenAlex), not a Clarivate Impact Factor. Always verify against the journal's official site before relying on it. See our Methodology or report a correction.
Compare Journals
Compare Advances in Therapy against similar publications in its field:
Related Journals in Your Field
-
Respiratory Research BioMed Central IF 4.80
-
BMJ Open Diabetes Research & Care BMJ IF 4.32
-
Inflammation Springer Science+Business Media IF 4.16
-
Survey of Ophthalmology Elsevier BV IF 4.11
-
BMJ Open Ophthalmology BMJ IF 2.88
Explore More Journals
Metadata
Last updated: Apr 24, 2026
Updated by: openalex_bulk
OpenAlex ID: S27230875
Get weekly updates for Asthma and respiratory diseases journals
Free. Monday morning. New citation rates, CFPs, indexing alerts, predatory watch list. One-click unsubscribe.